Post

New research · Internal Medicine
Thrombosis research · 3h
Cohort studyThrombosis research · 2026

Descriptive analysis of the Nationwide START2 antiphospholipid registry: Clinical and laboratory characteristics of patients with persistently positive antiphospholipid antibodies.

Vittorio Pengo, Daniela Poli, Luca Sarti … Start2 Antiphospholipid Registry collaborators, all in Italy
Read paper
Internal MedicineCohort study

Isolated lupus anticoagulant positivity linked to higher venous thromboembolism rates in antiphospholipid syndrome

Descriptive analysis of the Nationwide START2 antiphospholipid registry: Clinical and laboratory characteristics of patients with persistently positive antiphospholipid antibodies.

Vittorio Pengo … Start2 Antiphospholipid Registry collaborators, all in Italy
Thrombosis research · 2026
Background

The clinical significance of persistently positive antiphospholipid antibodies (aPLs) remains incompletely defined.

Purpose

To describe the clinical and laboratory characteristics of patients with confirmed aPL positivity enrolled in the nationwide START2 Antiphospholipid Registry.

Methods

Were categorized as Antiphospholipis Syndrome (Antiphospholipis Syndrome) or aPL carriers.

n = 500 enrolled patients
67%
Results
67%
isolated LA positivity carried the highest venous thromboembolism rate of any antibody pattern
n = 500 enrolled patients
More results

Women were overrepresented among carriers (76% vs 62%, p = 0.002).

Laboratory profiles were similarly distributed across Antiphospholipis Syndrome and carriers: triple positivity (43% vs 44%), double positivity (13% vs 12%), and isolated LA positivity (23% vs 30%).

More results

After a first venous thromboembolism, most Antiphospholipis Syndrome patients received warfarin (62%), whereas arterial Antiphospholipis Syndrome was treated with either warfarin (51%) or aspirin (37%).

Among carriers, aspirin was the preferred prophylactic strategy (45%).

“
Conclusion · 1 of 2

Triple, double, and LA positive only represent the most common laboratory patterns. LA positivity omly shows a disproportionately high rate of venous thromboembolism.

Conclusion · 2 of 2

Non-criteria manifestations remain more common in Antiphospholipis Syndrome. Substantial variability persists in antithrombotic management, underscoring the need for prospective treatment trials.

Read paper
0 comments

No comments yet. Be the first.

Related papers

LatestFoundational
Cohort Study
13.5%
Central retinal artery peak blood-flow speed was 13.5% lower in diabetic patients.
Cohort Study
4.5 minutes
Each visual-field test averaged 4.5 minutes per eye.
Review
46.7%
nearly half of thyroid patients had Graves' disease, the most common overactive-thyroid condition
Cross-sectional
MYR 88,346.12
Average annual out-of-pocket expenditure for patients with cancer in Malaysia.
Case-control
5.4% Reduction in Odds of Neuropathy
each rise in zinc levels lowers the chance of nerve damage
Cross-sectional
SIR 9.93
risk climbs sharply when relatives cluster and clotting starts young
Cohort Study
67.8%
one-year survival was far worse than the intermediate-risk group's, roughly one in three died
Systematic Review
“Current evidence does not support universal thromboprophylaxis following ACLR.”